Health Canada Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes Patients
Health Canada has granted a new indication for Eli Lilly's (LLY) Mounjaro (tirzepatide), allowing its use to reduce the risk of major adverse cardiovascular events. This approval specifically targets individuals living with both type 2 diabetes and established cardiovascular disease. The regulatory decision was supported by clinical data from the SURPASS-CVOT trial, which demonstrated the drug's efficacy in mitigating cardiovascular risks within this patient population. This expansion strengthens Mounjaro's position in the metabolic health market by addressing broader systemic complications associated with diabetes.

Tickers: $LLY
Topics: cardiovascular health diabetes treatment FDA approval
Read the full article at Seeking Alpha
Part of the story Health Canada Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes Patients (2 articles)